Pacira BioSciences (PCRX) Cash & Equivalents Growth (1y) (2011 - 2026)
Pacira BioSciences (PCRX) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | -39.02% |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 120.45% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 12.78% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 50.32% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -32.64% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 138.97% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 37.30% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -12.11% |
| 10 | Pacira BioSciences | 1.08 Bn | 876.91 Mn | 140.96 Mn | -49.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.12% |
| Dec 31, 2025 | -42.72% |
| Sep 30, 2025 | -40.00% |
| Jun 30, 2025 | 21.63% |
| Mar 31, 2025 | 54.09% |
| Dec 31, 2024 | 80.55% |
| Sep 30, 2024 | 148.15% |
| Jun 30, 2024 | 184.59% |
| Mar 31, 2024 | 417.80% |
| Dec 31, 2023 | 47.21% |
| Sep 30, 2023 | -9.42% |
| Jun 30, 2023 | -28.88% |
| Mar 31, 2023 | -84.32% |
| Dec 31, 2022 | -82.22% |
| Sep 30, 2022 | -18.36% |
| Jun 30, 2022 | 15.40% |
| Mar 31, 2022 | 239.96% |
| Dec 31, 2021 | 485.83% |
| Sep 30, 2021 | 7.02% |
| Jun 30, 2021 | 34.65% |